Twist Bioscience Corporation: Business Overview, Financials & Competitive Analysis
Twist Bioscience Corporation scores 7/10 on the AskCyborg Cyborg Score (Strong). AI-driven drug discovery and growing customer adoption position Twist for accelerating growth toward profitability in 2026. Twist reported 17% revenue growth to $103.7M in Q1 FY2026 with 52% gross margin and is benefiting from AI-enabled discovery trends. The company targets EBITDA breakeven in Q4 2026 with gross margins expected.
What is Twist Bioscience Corporation's industry? Twist Bioscience Corporation (twistbioscience.com) operates in Synthetic Biology / Biotech Tools & Services. AskCyborg classifies Twist Bioscience Corporation under Synthetic Biology / Biotech Tools & Services in its company registry.
Twist Bioscience is a leader in synthetic biology with a proprietary semiconductor-based DNA synthesis platform that produces high-quality synthetic DNA at faster rates and more affordably than traditional methods, se...
Cyborg Score thesis
AI-driven drug discovery and growing customer adoption position Twist for accelerating growth toward profitability in...
Read the full analyst-debate transcript →Get the Latest Twist Bioscience Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeTwist Bioscience Corporation Overview
Pro stress-test →Twist Bioscience is a leader in synthetic biology with a proprietary semiconductor-based DNA synthesis platform that produces high-quality synthetic DNA at faster rates and more affordably than traditional methods, serving applications in therapeutics, diagnostics, and academic research. The company is experiencing substantial AI-driven demand growth, with AI expected to become a primary step in drug discovery, reducing time and cost compared to traditional methods.
Strategic Profile
Pro stress-test →The company's ability to write DNA on silicon chips combined with proprietary software and e-commerce platform creates a highly scalable manufacturing process with significant cost advantages. Twist is targeting adjusted EBITDA breakeven by Q4 fiscal 2026 while driving toward sustained and profitable growth.
Competitive Landscape
Pro stress-test →Twist Bioscience has established itself as a leader in synthetic biology through its proprietary semiconductor-based DNA synthesis platform that produces DNA at faster rates and lower costs, giving it competitive advantage in the synthetic biology market. Key competitors include Ginkgo Bioworks and Synthego in synthetic biology, and larger players like Illumina in DNA sequencing.
Industry Context
Twist Bioscience Corporation operates in Synthetic Biology / Biotech Tools & Services.
Key facts
Founded: 2013 · Headquarters: South San Francisco, United States · Revenue: $103.7M (Q1 FY2026)